# Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

> **NCT06676319** · PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 1147 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Lunsekimig
- **DRUG:** Short-Acting Beta Agonists (SABA)
- **DRUG:** Placebo
- **DRUG:** Fluticasone/Salmeterol
- **DRUG:** Budesonide/Formoterol
- **DRUG:** Budesonide/Albuterol

## Key facts

- **NCT ID:** NCT06676319
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2027-09-17
- **Final completion:** 2027-10-15
- **Target enrollment:** 1147 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06676319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06676319, "Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06676319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*